Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction
Primary Purpose
Myocardial Infarction
Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Simvastatin
Ezetimibe-Simvastatin
Sponsored by
About this trial
This is an interventional prevention trial for Myocardial Infarction focused on measuring myocardial infarction, systemic inflammatory activity, endothelial function
Eligibility Criteria
Inclusion Criteria:
- less than 24 hours after the onset of myocardial infarction symptoms
- ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
- myocardial necrosis, as evidenced by increased CK-MB and troponin levels
Exclusion Criteria:
- use of statins for the last 6 months before myocardial infarction
Sites / Locations
- Hospital de Base do Distrito Federal
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ezetimibe-Simvastatin 10/40 mg
Simvastatin 40 mg
Arm Description
Outcomes
Primary Outcome Measures
C- reactive Protein (CRP) elevation during the first 7 days after myocardial infarction
Secondary Outcome Measures
Endothelial function 30 days after myocardial infarction
Stress Insulin Resistance
Evaluation of the change in plasma glucose, insulin and C-peptide from admission to the fifth day after myocardial infarction
Full Information
NCT ID
NCT00905905
First Posted
May 20, 2009
Last Updated
March 23, 2010
Sponsor
Brasilia Heart Study Group
1. Study Identification
Unique Protocol Identification Number
NCT00905905
Brief Title
Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction
Official Title
Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction
Study Type
Interventional
2. Study Status
Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
January 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Brasilia Heart Study Group
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
During acute coronary syndromes (ACS), the generation of inflammatory mediators negatively influences arterial wall remodeling and the endothelium-dependent vasomotor function in the coronary and systemic arterial systems. In fact, the intensity of the inflammatory upregulation is strongly related to the incidence of recurrent coronary events. The investigators previously demonstrated that high dose potent statins can rapidly reduce plasma levels of cholesterol-rich lipoproteins and inflammatory activity in subjects during ACS. In addition, such statin treatment attenuates the post-discharge endothelial dysfunction of these patients. By inference, it is plausible to hypothesize that these beneficial effects during ACS may be intensified by an additive lowering of plasma cholesterol through the treatment with ezetimibe. So far, data is unavailable to verify this assumption. In parallel, data from animal models have suggested that both statins and ezetimibe may reduce insulin sensitivity by their effect on cholesterol content and, by this way, on insulin signaling in liver cells. In this context, the present study aims to investigate the role of the addition of ezetimibe upon statin treatment on stress-induced insulin resistance and on the time-course of the inflammatory response during the acute phase of myocardial infarction and its late effect on endothelium-dependent arterial dilation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction
Keywords
myocardial infarction, systemic inflammatory activity, endothelial function
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ezetimibe-Simvastatin 10/40 mg
Arm Type
Experimental
Arm Title
Simvastatin 40 mg
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Simvastatin
Other Intervention Name(s)
Statin, Zocor
Intervention Description
Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Intervention Type
Drug
Intervention Name(s)
Ezetimibe-Simvastatin
Other Intervention Name(s)
Vytorin
Intervention Description
Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Primary Outcome Measure Information:
Title
C- reactive Protein (CRP) elevation during the first 7 days after myocardial infarction
Time Frame
5th day
Secondary Outcome Measure Information:
Title
Endothelial function 30 days after myocardial infarction
Time Frame
30th day
Title
Stress Insulin Resistance
Description
Evaluation of the change in plasma glucose, insulin and C-peptide from admission to the fifth day after myocardial infarction
Time Frame
5th day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
less than 24 hours after the onset of myocardial infarction symptoms
ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
myocardial necrosis, as evidenced by increased CK-MB and troponin levels
Exclusion Criteria:
use of statins for the last 6 months before myocardial infarction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrei C Sposito, MD, PhD
Organizational Affiliation
University of Brasilia Medical School
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital de Base do Distrito Federal
City
Brasilia
State/Province
DF
ZIP/Postal Code
70673103
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction
We'll reach out to this number within 24 hrs